Cel Sci (CVM) Accounts Payables (2010 - 2026)
Cel Sci (CVM) posted Accounts Payables of $933788.0 for Q1 2026, down 9.76% sequentially from $1.0 million in Q4 2025, and down 45.14% YoY from $1.7 million in Q1 2025.
Cel Sci (CVM) Accounts Payables (2010 - 2026) Analysis & Trends
Cel Sci has reported Accounts Payables for 16 years, with the latest figure at $933788.0 in Q1 2026.
- Quarterly Accounts Payables fell 45.14% year-over-year to $933788.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $933788.0 (down 45.14% YoY) and the FY2025 annual result came in at $1.1 million, down 26.73% from the prior year.
- Accounts Payables declined to $933788.0 in Q1 2026 per CVM's latest filing, from $1.0 million in the prior quarter.
- Over five years, Accounts Payables peaked at $2.0 million in Q3 2023 and troughed at $852860.0 in Q2 2022.
- A 5-year average of $1.4 million and a median of $1.4 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables tumbled 60.23% in 2022, then soared 104.33% in 2023.
- Over 5 years, Accounts Payables stood at $1.6 million in 2022, then decreased by 28.47% to $1.1 million in 2023, then surged by 74.69% to $2.0 million in 2024, then sank by 48.24% to $1.0 million in 2025, then dropped by 9.76% to $933788.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $933788.0, $1.0 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 933,788.00 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | 1.45 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 2.01 Mn |
| Jun 30, 2023 | 1.74 Mn |
| Mar 31, 2023 | 1.89 Mn |
| Dec 31, 2022 | 1.60 Mn |
| Sep 30, 2022 | 1.62 Mn |
| Jun 30, 2022 | 852,860.00 |
| Mar 31, 2022 | 1.32 Mn |
| Dec 31, 2021 | 1.19 Mn |
| Sep 30, 2021 | 1.68 Mn |
| Jun 30, 2021 | 2.14 Mn |